Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
42.05
USD
|
-0.12%
|
|
-0.02%
|
-0.83%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,108
|
4,773
|
4,928
|
7,659
|
7,661
|
-
|
-
|
Enterprise Value (EV)
1 |
1,724
|
4,208
|
4,313
|
6,820
|
7,042
|
6,971
|
7,661
|
P/E ratio
|
-8.25
x
|
-19.6
x
|
-13.6
x
|
-15.9
x
|
-14.3
x
|
-14.6
x
|
-15
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
126
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
126
x
|
EV / EBITDA
|
-11.6
x
|
-19.4
x
|
-11.9
x
|
-15.4
x
|
-15.2
x
|
-12.5
x
|
-14.1
x
|
EV / FCF
|
-12.6
x
|
-22.3
x
|
-14.5
x
|
-19.7
x
|
-23.7
x
|
-14
x
|
-16.5
x
|
FCF Yield
|
-7.93%
|
-4.49%
|
-6.89%
|
-5.07%
|
-4.21%
|
-7.12%
|
-6.06%
|
Price to Book
|
-
|
8.28
x
|
9.47
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
127,124
|
147,236
|
156,244
|
180,634
|
182,195
|
-
|
-
|
Reference price
2 |
16.58
|
32.42
|
31.54
|
42.40
|
42.05
|
42.05
|
42.05
|
Announcement Date
|
3/24/21
|
3/1/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
60.72
|
EBITDA
1 |
-148.7
|
-217.4
|
-362.9
|
-441.6
|
-463.8
|
-556.9
|
-544.2
|
EBIT
1 |
-149.1
|
-220.1
|
-367.8
|
-447.3
|
-528.9
|
-553.4
|
-540.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-889.77%
|
Earnings before Tax (EBT)
1 |
-152.2
|
-225.3
|
-351.4
|
-432.3
|
-447.7
|
-547.5
|
-564.9
|
Net income
1 |
-152.1
|
-225.3
|
-351.5
|
-432.8
|
-523.2
|
-559.4
|
-578.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-952.17%
|
EPS
2 |
-2.010
|
-1.650
|
-2.320
|
-2.670
|
-2.945
|
-2.877
|
-2.806
|
Free Cash Flow
1 |
-136.7
|
-189
|
-297.1
|
-346.1
|
-296.7
|
-496.3
|
-464.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-764.46%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/21
|
3/1/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-93.8
|
-106
|
-
|
-
|
-109.9
|
-138.1
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-64.49
|
-72.53
|
-93.01
|
-95.06
|
-107.2
|
-99.55
|
-96.84
|
-111.3
|
-139.6
|
-142.7
|
-145
|
-149
|
-150
|
-125
|
-128
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-59.06
|
-68.29
|
-90.47
|
-99.94
|
-92.65
|
-104.2
|
-99.43
|
-96.24
|
-132.5
|
-131.8
|
-108.6
|
-113.3
|
-114.7
|
-123
|
-126
|
Net income
1 |
-59.06
|
-68.29
|
-90.47
|
-99.94
|
-92.81
|
-104.3
|
-99.54
|
-96.36
|
-132.7
|
-131.9
|
-145
|
-133
|
-181
|
-123
|
-126
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4000
|
-0.4600
|
-0.6100
|
-0.6600
|
-0.5900
|
-0.6700
|
-0.6300
|
-0.6100
|
-0.7600
|
-0.7300
|
-0.8000
|
-0.7300
|
-0.9900
|
-0.7200
|
-0.7300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/10/22
|
8/1/22
|
11/8/22
|
2/22/23
|
5/3/23
|
8/2/23
|
11/1/23
|
2/27/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
384
|
566
|
615
|
839
|
619
|
690
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-137
|
-189
|
-297
|
-346
|
-297
|
-496
|
-464
|
ROE (net income / shareholders' equity)
|
-
|
-46.8%
|
-63.9%
|
-72.4%
|
-64.7%
|
-69.1%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-39.7%
|
-41.2%
|
-38.3%
|
-35.4%
|
-38.3%
|
-
|
Assets
1 |
-
|
567.1
|
853.4
|
1,131
|
1,477
|
1,461
|
-
|
Book Value Per Share
|
-
|
3.920
|
3.330
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-2.110
|
-2.300
|
-
|
-
|
Capex
1 |
18.9
|
10.5
|
3.95
|
3.81
|
9.9
|
10.6
|
7.9
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
13.01%
|
Announcement Date
|
3/24/21
|
3/1/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
42.05
USD Average target price
44.78
USD Spread / Average Target +6.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -0.83% | 7.67B | | +9.58% | 115B | | +12.41% | 106B | | -2.59% | 21.96B | | -12.38% | 21.87B | | -5.29% | 19.21B | | -3.35% | 18.08B | | -38.57% | 17.71B | | +7.51% | 14.32B | | +35.67% | 12.42B |
Bio Therapeutic Drugs
|